Table 3. B19V seroprevalence among RA patients and healthy persons.
Percentage of persons with antibodies to parvovirus B19 VP2 protein (detected using Biotrin ELISA kit) and to various parvovirus B19 antigens (detected using Mikrogen recomLine kit). B19+ RA patients were divided into the groups according to the viral DNA findings: in blood and cell-free blood plasma (b/p), blood (b) and cell-free blood plasma (p). N, Number of persons; B19+, parvovirus B19 DNA positive; B19−, parvovirus B19 DNA negative; Contr., healthy controls.
| All investigated samples | Samples tested by recomLine dot blot | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | Positive in VP2 ELISA | N | Positive in VP2 ELISA | Positive in recomLine dot blot | ||||||||||||||
| VP-2P | VP-N | VP-1S | VP-2r | VP-C | NS-1 | |||||||||||||
| N | % | N | % | N | % | N | % | N | % | N | % | N | % | N | % | |||
| IgG antibodies to B19V proteins | ||||||||||||||||||
| RA B19+b/p | 8 | 7 | 87.5 | 4 | 3 | 75.0 | 3 | 75.0 | 2 | 50.0 | 2 | 50.0 | 2 | 50.0 | 0 | 0 | 0 | 0 |
| RA B19+b | 6 | 5 | 83.3 | 5 | 5 | 100 | 5 | 100 | 4 | 80.0 | 4 | 80.0 | 1 | 20.0 | 0 | 0 | 0 | 0 |
| RA B19+p | 16 | 15 | 93.8 | 13 | 12 | 92.3 | 9 | 69.2 | 6 | 46.2 | 5 | 38.5 | 2 | 15.4 | 0 | 0 | 0 | 0 |
| RA B19+ | 30 | 27 | 90.0 | 22 | 20 | 90.9 | 17 | 77.3 | 12 | 54.5 | 11 | 50.0 | 5 | 22.7 | 0 | 0 | 0 | 0 |
| RA B19− | 88 | 76 | 86.4 | 33 | 31 | 93.9 | 22 | 66.7 | 18 | 54.5 | 14 | 42.4 | 5 | 15.2 | 1 | 3.0 | 1 | 3.0 |
| Contr. B19+ | 9 | 7 | 77.8 | 9 | 7 | 77.8 | 7 | 77.8 | 6 | 66.7 | 6 | 66.7 | 0 | 0 | 0 | 0 | 0 | 0 |
| Contr. B19− | 44 | 36 | 81.8 | 19 | 19 | 100 | 13 | 68.4 | 11 | 57.9 | 11 | 57.9 | 3 | 15.8 | 1 | 5.3 | 2 | 10.5 |
| IgM antibodies to B19V proteins | ||||||||||||||||||
| RA B19+b/p | 8 | 0 | 0 | 4 | 0 | 0 | 2 | 50.0 | 2 | 50.0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| RA B19+b | 6 | 0 | 0 | 5 | 0 | 0 | 2 | 40.0 | 0 | 0 | 0 | 0 | 1 | 20.0 | 0 | 0 | 0 | 0 |
| RA B19+p | 16 | 0 | 0 | 9 | 0 | 0 | 2 | 22.2 | 3 | 33.3 | 2 | 22.2 | 0 | 0 | 0 | 0 | 0 | 0 |
| RA B19+ | 30 | 0 | 0 | 18 | 0 | 0 | 6 | 33.3 | 5 | 27.8 | 2 | 11.1 | 1 | 5.6 | 0 | 0 | 0 | 0 |
| RA B19− | 88 | 0 | 0 | 12 | 0 | 0 | 5 | 41.7 | 2 | 16.7 | 0 | 0 | 1 | 8.3 | 0 | 0 | 0 | 0 |
| Contr. B19+ | 9 | 0 | 0 | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Contr. B19− | 44 | 0 | 0 | 11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |